Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.
You may also be interested in...
Obesity Drug Developers Aim To Navigate Regulatory Backroads
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.
Obesity Drug Developers Aim To Navigate Regulatory Backroads
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.
Arena Lays Out Path Forward For Lorcaserin
Arena Pharmaceuticals and Japanese partner Eisai plan to resubmit an NDA for the controversial obesity drug lorcaserin by the end of 2011.